The findings provide insight into which patients may have favorable or inferior responses to immunotherapy for small cell ...

A federal judge is considering the 47th presidential administration’s request to unseal FBI surveillance records on Martin Luther King Jr.—currently sealed until 2027—amid opposition from King’s ...

While the approval is a historic event for the BiTE drug class in solid tumours, the market share opportunity is restricted ...

A new study is the first phase 3 to show meaningful improvement in both progression-free and overall survival with first-line ...

Jazz Pharma and PharmaMar have revealed the overall survival (OS) data for their chemotherapy drug Zepzelca in ...

BeOne Medicines' robust financial outlook is driven by zanubrutinib's rapid sales growth and anticipated positive cash flow.

The latest news from ASCO 2025 focusing on SCLC including abstracts, features, and helpful conference information.

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced positive results from the Phase III IMforte study of Tecentriq (atezolizumab) in combination with lurbinectedin (Zepzelca) as a fi ...

Eared Books. How did a white guy from Iowa decide to write a book about a crucial period in the civil rights ...

For the first time in years, small cell lung cancer (SCLC) patients have reason for renewed hope. Exciting new research ...

Phase 3 trial shows lurbinectedin plus atezolizumab significantly improves progression-free and overall survival in ES-SCLC ...